- The Wall Street Journal•2 days ago
A panel of experts in engineering and medical devices will help the embattled blood-testing company to review its product designs. Last year, it created an advisory panel on scientific and medical issues....
- PR Newswire•11 days agoAcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif., Jan. 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, provided guidance today on 2017 milestones for its lead product, ARX-04, known as DSUVIA™ (sufentanil sublingual tablet, 30 mcg) in the United States. Advance the NDA. AcelRx submitted a 505(b)2 new drug application (NDA) for DSUVIA for moderate-to-severe acute pain in a medically supervised setting on December 12, 2016.
- PR Newswire•11 days ago
REDWOOD CITY, Calif., Jan. 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
ACRX : Summary for AcelRx Pharmaceuticals, Inc. - Yahoo Finance
AcelRx Pharmaceuticals, Inc. (ACRX)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.70 x 9800|
|Ask||2.75 x 400|
|Day's Range||2.70 - 2.75|
|52 Week Range||2.40 - 4.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.82|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|